97 related articles for article (PubMed ID: 9831792)
1. Water as a tumoricidal agent in bladder cancer. In vitro studies in parental and resistant cell lines.
Solomon LZ; Birch BR; Cooper AJ
Eur Urol; 1998 Dec; 34(6):500-4. PubMed ID: 9831792
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Solomon LZ; Jennings AM; Foley SJ; Birch BR; Cooper AJ
Br J Urol; 1998 Jul; 82(1):122-6. PubMed ID: 9698674
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
[TBL] [Abstract][Full Text] [Related]
4. Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
Jennings AM; Solomon LZ; Sharpe P; Hayes MC; Cooper AJ; Birch BR
Eur Urol; 1999 Apr; 35(4):327-35. PubMed ID: 10087397
[TBL] [Abstract][Full Text] [Related]
5. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
7. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
[TBL] [Abstract][Full Text] [Related]
8. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
[TBL] [Abstract][Full Text] [Related]
9. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Popert RJ; Masters JR; Coptcoat M; Zupi G
Urol Res; 1995; 22(6):367-72. PubMed ID: 7740656
[TBL] [Abstract][Full Text] [Related]
10. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
11. Establishment of doxorubicin-resistant human bladder cancer cell line (BUI-87/ADMR) and its mechanism of multidrug resistance.
Guo H; Lu G; Xiong X; Dong J; Liu S
Chin Med J (Engl); 1997 Mar; 110(3):167-72. PubMed ID: 9594332
[TBL] [Abstract][Full Text] [Related]
12. Intravesical chemotherapy with gamma linolenic acid becomes a realistic prospect in serum-free applications: in vitro cytotoxicity and systemic absorption studies.
Solomon LZ; Jennings AM; Sharpe P; Cooper AJ; Birch BR
J Urol; 1998 Dec; 160(6 Pt 1):2280-3. PubMed ID: 9817384
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
[TBL] [Abstract][Full Text] [Related]
14. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Speers AG; Lwaleed BA; Featherstone JM; Sallis BJ; Cooper AJ
J Clin Pathol; 2006 Sep; 59(9):912-5. PubMed ID: 16556663
[TBL] [Abstract][Full Text] [Related]
15. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
[TBL] [Abstract][Full Text] [Related]
16. Progesterone: a novel adjunct to intravesical chemotherapy.
Lewin J; Cooper A; Birch B
BJU Int; 2002 Nov; 90(7):736-41. PubMed ID: 12410758
[TBL] [Abstract][Full Text] [Related]
17. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Duffy PM; Hayes MC; Gatrell SK; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):824-9. PubMed ID: 8705215
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implications and applications.
Benson MC; Giella J; Whang IS; Buttyan R; Hensle TW; Karp F; Olsson CA
J Urol; 1991 Oct; 146(4):982-6; discussion 986-7. PubMed ID: 1680203
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Birare N; Lwaleed BA; Cooper AJ
J Urol; 2009 Nov; 182(5):2472-6. PubMed ID: 19765756
[TBL] [Abstract][Full Text] [Related]
20. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1).
Hayes MC; Birch BR; Cooper AJ; Primrose JN
BJU Int; 2001 Feb; 87(3):245-50. PubMed ID: 11167651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
